Dupixent Use May Increase Risk of Rare Skin Cancer

• Signals in medical literature: Some case reports describe patients treated for presumed eczema whose disease later proved to be CTCL, occasionally recognized after starting biologic therapy.
• Several recent studies raised alarms: an April 2024 study, published in JAMA Dermatology, found a 300% higher risk of CTCL among Dupixent users, while an August 2024 study reported a 350% increase. A June 2025 asthma study found even higher risks, up to 14-fold in long-term users.
• Diagnostic complexity: CTCL can mimic eczema; persistent or changing rashes often require biopsy and dermatopathology review.
• Legal questions: Claims may allege that Dupixent exposure unmasked or accelerated underlying CTCL and that warnings were inadequate.
• FDA Database: The FDA's adverse event database has logged nearly 300 lymphoma reports tied to Dupixent, including 138 confirmed CTCL cases.

A viable claim focuses on your individual medical timeline and what the manufacturer knew or should have known—not on universal causation.

Do I Have a Dupixent T‑Cell Lymphoma Case?

You may qualify for investigation if you meet some of the following:

• Documented Dupixent (dupilumab) use before diagnosis
• Diagnosis of CTCL (mycosis fungoides, Sézary syndrome) or other T‑cell lymphoma
• Worsening or non‑resolving dermatitis on Dupixent with new plaques/patches, lymphadenopathy, night sweats, or weight loss
• Biopsy‑proven lymphoma and dermatopathology supporting CTCL
• Medical records showing the timeline: first Dupixent dose → evolving symptoms → diagnosis

Unsure if you qualify? We will review your history free of charge.

Legal Theories We Investigate

• Failure to warn / inadequate warnings
• Design defect (where applicable)
• Negligence / negligent misrepresentation
• Breach of warranty
• Consumer‑protection violations (state‑specific)

Deadlines apply. Statutes of limitations and repose can bar claims if you wait. Contact us as soon as possible.

Potential Compensation

• Medical expenses (past and future)
• Lost wages and diminished earning capacity
• Pain and suffering; loss of enjoyment of life
• Caregiving and out‑of‑pocket costs
• Wrongful death damages for eligible families

What to Do If You Suspect CTCL After Dupixent

1. Seek medical care with dermatology/oncology and consider biopsy review by an experienced dermatopathologist.
2. Preserve evidence: injection dates, pharmacy receipts, photos, pathology reports and slide IDs.
3. Contact Boling Law Firm for a confidential review. We obtain records and consult experts where appropriate.

Dupixent & T‑Cell Lymphoma: FAQs

Does Dupixent cause T‑cell lymphoma?

Evidence is evolving and case‑specific. Some reports describe CTCL recognized after biologic therapy for presumed eczema. Lawsuits examine what was known, the adequacy of warnings, and your individual timeline.

What is CTCL?

Cutaneous T‑cell lymphoma is a rare non‑Hodgkin lymphoma involving the skin (e.g., mycosis fungoides, Sézary syndrome). It often resembles eczema and requires specialized biopsy and immunophenotyping for diagnosis.

I took Dupixent for asthma or nasal polyps—can I qualify?

Possibly. Eligibility depends on exposure history, symptom progression, and diagnosis. We evaluate all indications of Dupixent use.

How long do I have to file?

Deadlines vary by state and can be short. Speak with an attorney promptly to preserve your rights.

What does it cost to hire Boling Law Firm?

Nothing upfront. We work on a contingency fee—you pay nothing unless we obtain a recovery for you.